Skip to content

Attentional Impairment in People With Epilepsy

Attentional Impairment in People With Epilepsy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04379128
Acronym
ETAPE
Enrollment
272
Registered
2020-05-07
Start date
2020-05-31
Completion date
2025-08-31
Last updated
2020-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Brief summary

Epilepsy is one of the most common chronic neurological conditions.It leads to cognitive impairment in 20-50% of patients with a structural form. In comparison with seizures, these cognitive disorders are a major additional factor in occupational, social and family disability. They are particularly frequent (50%) in temporal epilepsies and preferably concern memory and language skills. The cognitive consequences of epilepsy are therefore well described in the following areas: episodic memory, language, executive functions. Concerning attentional abilities, a recent review has highlighted the lack of work in this specific field in order to properly measure the prevalence and nature of attentional disorders in epileptic patients. Indeed, attentional abilities are often mentioned in studies, but attention is a complex domain defined by four modalities: alertness, selective attention, divided attention and sustained attention. No study systematically assesses all of these modalities. The objective of this study is to evaluate the prevalence and nature of attentional disorders in epileptic patients compared to control subjects.

Interventions

OTHERAttentional tasks

a neuropsychological assessment of attentional task, executive task and interview is proposed to patients or normal control

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Patients: Inclusion Criteria: * Patient with epilepsy, according to Fisher et al. (2005). * Patient with written informed consent * affiliation to a social security regime is compulsory * Individuals who have received full information about the organization of the research and have not objected to their participation and the use of their data. * Patient 18 years of age and older Normal controls: Individuals who have received full information about the organization of the research and have not objected to their participation and the use of their data. * People 18 years of age and older * People with no neurological and/or psychiatric history

Exclusion criteria

for patients: with another progressive neurological condition for all People of full age who are subject to a legal protection measure or who are unable to express their consent People deprived of their liberty by a judicial or administrative decision People who regularly use psychoactive substances (cannabis, alcohol...)

Design outcomes

Primary

MeasureTime frameDescription
d2-r10 minutesselective attention task

Secondary

MeasureTime frameDescription
sustained attention TAP Subtest15 minutesYour task is to press the key as quickly as possible whenever two successive patterns have the same shape
alertness attention TAP Subtest8 minutesa cross appears on the screen. press the key when the cross appears
divided attention TAP Subtest5 minutesfirst task :a cross appears on the screen in which a varying number of crosses appear simultaneously. when four of these crosses form a square, then please press the key as quickly as possible. second task: in this task you will hear a high and a low tone in sequence. you must decide whether the same tone occurs twice in a row. Please press the key as quickly as possible.

Other

MeasureTime frameDescription
Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)3 minutesDepression scale score 0 to 24
digit span5 minutesimmediate memory task
GENERALIZED ANXIETY DISORDER (GAD-7)3 minutesANXIETY scale score : 0 to 21
verbal fluency5 minutesexecutive task
incompatibility TAP subtest8 minutesexecutive task
flexibility TAP subtest8 minutesexecutive task

Contacts

Primary Contacthelene BRISSART, Dr
h.brissart@chru-nancy.fr383851689

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026